Protocol No.: A041703

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for PH-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
Principal Investigator
Ross, Kelly
Phase
II (Cancer Control)
Age Group
Adult
Applicable Disease Site
Leukemia
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Abby Swiger, RN
Research Nurse
Phone: +1 304-293-1683

View on ClinicalTrials.gov